GlaxoSmithKline and the U.S. FDA have sent a letter to doctors warning that the antidepressant Paxil could increase the risk of suicidal behavior in young adults.
During clinical trials testing the drug, there were 11 suicide attempts made by participants taking Paxil, compared to only one suicide attempt among those taking a placebo. The 18-30 age group was at the highest risk, accounting for eight of the 11 Paxil-related incidents.
Most antidepressants currently have labels warning patients of the risk of suicidal behavior. The FDA has stressed that patients taking Paxil should be carefully monitored.